Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Dogwood Therapeutics, Inc. Common Stock

DWTX

Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.

Last trade $1.18
Day change +$0.12 (+11.32%)
Day range $1.07 – $1.19
Volume 81,103
Market cap $41M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$40.52M
Price / earnings
—
Price / book
0.63×
Price / sales
405.22×
EV / sales
355.73×
EV / EBITDA
-1.91×

Profitability

Earnings per share
-$0.66
Return on assets
-33.3%
Return on equity
-39.26%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.78×
Quick ratio
2.78×
Cash ratio
2.28×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.47M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DWTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$100K$0$0$0$0$0$0$0
Cost of revenue$88.1K$0$0$0$0$0$0$0
Gross profit$11.9K$0$0$0$0$0$0$0
Selling, general and administrative$1.58M$1.63M$2.41M$1.47M$1.29M$1.35M$1.99M$5.23M
Research and development$3.35M$3.25M$2.67M$2.34M$14.52M$2.57M$2.44M$2.32M
Total operating expenses$4.93M$14.06M$5.08M$3.81M$15.81M$3.92M$4.43M$7.54M
Operating income-$4.92M-$14.06M-$5.08M-$3.81M-$15.81M-$3.92M-$4.43M-$7.54M
Interest expense$42.04K$66.35K$0$0$80.58K$111.38K$0$0
Income before taxes-$4.88M-$14.01M-$4.99M-$3.75M-$15.75M-$3.81M-$10.73M-$7.73M
Income taxes-$839-$2.48M$1.19K$31.84K-$1.44K$149$190.54K-$503
Net income-$4.88M-$11.53M-$4.99M-$3.78M-$15.74M-$3.81M-$10.92M-$7.73M
Net income attributable to common shareholders-$4.88M-$11.53M-$4.99M-$3.78M-$15.74M-$3.81M-$12.18M-$8.24M
EBITDA-$4.92M-$4.87M-$5.08M-$3.81M-$15.84M-$3.91M-$4.41M-$7.53M
Basic earnings per share-$0.14-$0.34-$0.15-$0.26-$8.20-$1.99-$8.45-$6.27
Diluted earnings per share-$0.14-$0.34-$0.15-$0.26-$8.20-$1.99-$8.45-$6.27

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight

DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.

GlobeNewswire Inc.

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Dogwood Therapeutics reported ongoing Phase 2b trial for Halneuron®, a potential treatment for chemotherapy-induced neuropathic pain, with 52 patients enrolled and interim data expected in Q4 2025. The company experienced increased research and development expenses and reported a net loss of $3.8 million for Q2 2025.

GlobeNewswire Inc.

Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

The sodium channel blocker market is expanding due to the increasing prevalence of neuropathic pain and the rising incidence of cardiac arrhythmias. Over 20 pharmaceutical companies are actively developing 25+ pipeline sodium channel blockers, with promising drugs like Cenobamate, VX-548, and Vormatrigine in different clinical trial phases.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.